Survival in male breast cancer over the past three decades
Menée à partir des données 1988-2017 des registres américains des cancers portant sur 8 481 hommes atteints d'un cancer du sein, cette étude analyse l'évolution de la survie spécifique et de la survie globale
Background: Breast cancer mortality in women has declined significantly over the past several years. In men, it is unclear whether survival has changed over time. We evaluated changes in breast cancer-specific survival (BCSS) and overall survival (OS) in male breast cancer (MaBC) over the past 3 decades. Methods: We evaluated men diagnosed with breast cancer between 1988 and 2017, reported in the Surveillance, Epidemiology, and End Results registry. Patients were categorized into 3 groups by year of diagnosis: 1988-1997, 1998-2007 and 2008-2017. BCSS and OS were estimated by Kaplan-Meier and differences between groups were compared by log-rank test. Multivariable Cox regression evaluated the independent association of year of diagnosis with BCSS and OS. All tests were 2-sided. Results: We included 8,481 men. Overall, BCSS at 5 years was 83.69%, 83.78% and 84.41% in groups 1988-1997, 1998-2007 and 2008-2017, respectively; P=.86. There was no significant difference in BCSS between the 3 groups within each stage of disease. Among all patients, OS at 5 years was 64.61%, 67.31% and 69.05% in groups 1988-1997, 1998-2007 and 2008-2017, respectively; P=.01. In adjusted Cox models, each additional year of diagnosis had no significant association with BCSS (hazard ratio, 1.00; 95% confidence interval: 0.99–1.01; P=.75), but there was significant improvement in OS (hazard ratio, 0.99; 95% CI: 0.98–0.99; P=.009). Conclusion: Over the past 3 decades, there has been no significant improvement in BCSS in MaBC. Changes in OS over time are consistent with increasing life expectancy. Efforts to improve BCSS in MaBC are warranted.